Old Web
English
Sign In
Acemap
>
authorDetail
>
Yanfang Liu
Yanfang Liu
Merck & Co.
Medicine
Oncology
treatment options
Renal cell carcinoma
Internal medicine
3
Papers
5
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.
2021
Journal of Clinical Oncology
Robert J. Motzer
Yanfang Liu
Rodolfo F. Perini
Yayan Zhang
Daniel Yick Chin Heng
Show All
Source
Cite
Save
Citations (0)
An open-label phase II study comparing two doses of MK-6482 for the treatment of advanced renal cell carcinoma (RCC) following progression on prior systemic therapy.
2021
Journal of Clinical Oncology
Michael B. Atkins
Yanfang Liu
Rodolfo F. Perini
Ananya Roy
John B. A. G. Haanen
Show All
Source
Cite
Save
Citations (0)
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
2021
Journal of Clinical Oncology
Ramaprasad Srinivasan
Frede Donskov
Othon Iliopoulos
Wendy Kimryn Rathmell
Vivek Narayan
Benjamin L. Maughan
Stéphane Oudard
Tobias Else
Jodi K. Maranchie
Sarah J. Welsh
Ananya Roy
Yanfang Liu
Rodolfo F. Perini
W. Marston Linehan
Eric Jonasch
Show All
Source
Cite
Save
Citations (5)
1